INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10626441		
Filing Date		2003-07-23		
First Named Inventor Stein		Lundby		
Art Unit		2611		
Examiner Name Tse,		foung Tol		
Attorney Docket Number		PA693C1		

			Remove			
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	08856428	A		Odenwalder	
	2	5764592	A	1998-06-09	McClure	
3		5654979	A	1997-08-05	Levin et al.	
	4	5506865	A	1996-04-09	Weaver	
	5	5490165	A	1996-02-06	Blakeney et al.	
	6 5109390 A 1992-04-2		1992-04-28	Gilhousen et al.		
	7	5102459	A	1992-04-07	Ritter et al.	
	8	5101501	A	1992-03-31	Gilhousen et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10626441	
Filing Date		2003-07-23	
First Named Inventor	Stein	Lundby	
Art Unit		2611	
Examiner Name	Tse, Y	foung Tol	
Attorney Docket Number		PA693C1	

	9	4901307	A	1990-02	1-13	Gilhousen et a	ı				
	10										
If you wish to add additional U.S. Patent citation information please click the Add button.											
U.S.PATENT APPLICATION PUBLICATIONS Remove											
Examiner Initial*	Examiner Cite No Publication Number Kind Codes Date of Cited Document of cited Document of Cited Document City Representations of Cited Document City Representations of Cited Document City Representations of City Represent										
	1										
If you wis	h to a	dd additional U.S. Publis	shed Ap	plication	citatio	n information p	lease click the Ad	d buttor	Add		
				FOREIG	SN PAT	TENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No						evant or Relevant	T4			
	1										
If you wis	h to ac	dd additional Foreign Pa	itent Do	cument	citation	information pl	ease click the Add	button	Add		
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Cite Initials* Cite Indude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.									T5		
1											
If you wish to add additional non-patent literature document citation information please click the Add button Add											

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Application Numb Filing Date First Named Inver Art Unit Examiner Name

Application Number		10626441
Filing Date		2003-07-23
First Named Inventor Stein		Lundby
Art Unit		2611
Examiner Name Tse, Y		Young To:
Attomory Docket Number		PAG03C1

	Attorney Docket Number	PA693C1				
EXAMINER SIGNATURE						
Examiner Signature		Date Considered				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kini. Close of USPTO Plantin Documents at year, USPTO, COV or MPEP 901.04. * Enter office that issued the document, by the two-letter code (WIPO) Standard 513... * For Legances periated counters, the inclusion or the year of the region of the Emperor must precise of the senior humber of the patient document. *
India of coursent by the appropriate symbols as indicated on the document under WIPO Standard 51.16 if possible. * Applicant is to place a check mark here it Employin larguages translation a statistical.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10626441	
Filing Date		2003-07-23	
First Named Inventor	Stein	Lundby	
Art Unit		2611	
Examiner Name Tse, Y		foung Toi	
Attorney Docket Number		PA693C1	

CERTIFICATION STATEMENT

DI	27	OFF	4 07	 4 00 4-	 appropriate	 - 1-

That each item of information contained in the information disclosure statement was first cited in any communication
from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/97(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- _ ...

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/George J. Oehling/	Date (YYYY-MM-DD)	2007-09-14
Name/Print	George J. Cehling	Registration Number	40471

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for lie fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1449, Alexandriv, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandriva, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the stacked form related to a petient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is civulating; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and the process of the process and the process of the pro

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these cords.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.